These observations have provided a strong rationale for combining CDK9 and BRD4 inhibitors, a concept that has shown promise in preclinical models of small-cell lung cancer, rhabdoid tumors and leukemia [67–69]. This evidence concerns the gene BRD4 and leukemia.